Skip to content
Screener

Phathom Pharmaceuticals, Inc. PHAT Q3 2026 earnings

Reported October 29, 2026 · Before market open

Revenue$84.7MMiss by $100.4K
EPS-$0.16Miss by $0.05
Revenue estimate$84.8M
EPS estimate-$0.11
“We are pleased to report continued solid revenue growth and improved operating profitability for the third quarter. We continue to grow VOQUEZNA prescribing depth among GI providers and have implemented several initiatives designed to make it easier for physicians to prescribe and patients to obtain our first-in-class GERD treatment. These efforts build on our commercial momentum, which includes recently reaching the milestone of two million VOQUEZNA prescriptions filled.”
Steve Basta

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full
Revenue$84.7M+71.1%
Gross profit$66.4M+53.2%
Operating income-$85.0K+99.4%
Net income-$13.9M+53.6%
EPS (diluted)-$0.16+61.0%

Balance sheet

See full
Cash & equivalents$184.6M+36.6%
Total debt$168.0M-19.9%
Total equity-$347.6M+17.7%
Total assets$345.0M+43.6%

Cash flow

See full
CapEx$110.0K+307%

Valuation & ratios

Valuation

as of 10/30/26
See full
Market cap$505.63M-46.5%
Enterprise value$489.03M-52.0%
P/S1.8×-4.6×

Profitability

See full
Gross margin80.7%-6.6pp
Operating margin-9.3%-4.5pp
Net margin-30.2%-13.8pp

Returns & leverage

See full
Current ratio1.8×-0.5×

Segments

By segment

See full
Reportable Segment Aggregation Before Other Operating$84.7M+71.1%

By product

See full
Voquezna Product$84.7M+71.1%

FAQ

When did Phathom Pharmaceuticals, Inc. report Q3 2026 earnings?
Phathom Pharmaceuticals, Inc. (PHAT) reported Q3 2026 earnings on October 29, 2026 before market open.
What were Phathom Pharmaceuticals, Inc.'s Q3 2026 revenue and EPS?
Phathom Pharmaceuticals, Inc. reported revenue of $84.7M and eps of $-0.16 for Q3 2026.
Did Phathom Pharmaceuticals, Inc. beat estimates in Q3 2026?
Revenue missed the consensus estimate of $84.8M by $100.4K. EPS missed the consensus estimate of $-0.11 by $0.05.
How did Phathom Pharmaceuticals, Inc.'s Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 71.1% from $49.5M a year earlier and eps declined 6.7% from $-0.15.
Where can I find Phathom Pharmaceuticals, Inc.'s Q3 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-430977) and the 10-Q periodic report (0001193125-26-436961) directly on SEC EDGAR. The filing index links above go to sec.gov.